🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. Telotristat Etiprate

    LEXICON PHARMACEUTICALS, INC.

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  2. Terbinafin "Moberg Pharma", kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terclara, kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea

    Pharma Mar S.A.

    Distal Subungual Onychomycosis

    phase 2 small molecule active

    1 trial

  3. Testosterone cypionate

    United Therapeutics Europe Ltd

    Castration Resistant Metastatic Prostate Cancer

    phase 2 small molecule completed

    1 trial

  4. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Pharma Mar S.A.

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  5. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Treatment-resistant Pruritus Associated With Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  6. Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets

    Takeda Pharmaceuticals International AG

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  7. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  8. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  9. YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Novartis Ophthalmics Europe

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  10. farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Eisai GmbH

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial

  11. teclistamab, JNJ-64407564, JNJ-64407564, teclistamab, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  12. teclistamab, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, teclistamab, Privigen 100 mg/ml solution for infusion

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  13. A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  14. A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  15. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  16. A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

    Janssen-Cilag International N.V.

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  17. A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer

    phase 1 other active

    1 trial

  18. A Phase I, randomized, controlled, Latin-square, open-label study, to evaluate the effect of ADV7103 on gastric pH under fed and fasting conditions in adult healthy participants.

    Advicenne S.A.

    distal renal tubular acidosis (dRTA)

    phase 1 other active

    1 trial

  19. A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497

    Pfizer Ireland Pharmaceuticals Unlimited Company

    small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), follicular lymphoma (FL)

    phase 1 other active

    1 trial

  20. A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

    AbbVie Deutschland GmbH & Co. KG

    Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  21. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Pharma Mar S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  22. A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Participants

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Small cell lung cancer, Castration-resistant prostate cancer, Follicular lymphoma

    phase 1 other active

    1 trial

  23. A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

    Otsuka Novel Products GmbH

    Tuberculosis

    phase 1 other active

    1 trial

  24. A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

    Stemline Therapeutics B.V.

    ​​Platinum-Resistant ovarian cancer​

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources